GT Biopharma, Inc.
GTBP· Nasdaq
GTBPGT Biopharma, Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001493152-26-037988
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$4.52M | -$30.17M | -$3.71M | -$1.99M |
| EPS Diluted | -$0.12 | -$10.92 | -$2.17 | -$1.49 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
